StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.31 | $0.30 | -1.43% | 1.0M |
| 05-12 | $0.30 | $0.30 | -0.64% | 0.4M |
| 05-13 | $0.30 | $0.30 | -2.57% | 0.3M |
| 05-14 | $0.30 | $0.30 | +0.61% | 0.2M |
| 05-15 | $0.29 | $0.29 | -2.75% | 0.2M |
Each factor shows IGC's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q2 2026 (Est.) Expected 2026-06-25 | Annual 2022 2022-03-31 |
|---|---|---|
Revenue | $264.12K | $289.00K |
Operating Income | Not available | $-15.43M |
Net Income | Not available | $-15.02M |
EPS (Diluted) | $-0.02 | Not available |
Total Assets | Not available | $26.83M |
Total Liabilities | Not available | $2.94M |
Cash & Equivalents | Not available | $10.46M |
Free Cash Flow OCF − CapEx | Not available | $-7.70M |
Shares Outstanding | Not available | 51.05M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.